Exabis Library
Welcome to the e-CCO Library!
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort study
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P425: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre study
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P425: Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P425: Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P425: The utility of intestinal ultrasound to inform clinical decision making
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P426: Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P426: Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant? 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulas
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of view
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P427: Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P427: Exploring phenotype and treatment of inflammatory bowel disease in the elderly
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM